Effects of Sulfasalazine in Axial Spondyloarthritis on COVID-19 Outcomes: Real-life Data from a Single Center.

Berkan ArmağanEbru AtalarSerdar Can GüvenBahar ÖzdemirHatice Ecem KonakPınar Akyüz DağlıAbdulsamet ErdenKevser GökYüksel Maraşİsmail DoğanOrhan KüçükşahinŞükran ErtenAhmet Omma

Published in: Immunopharmacology and immunotoxicology (2022)

Our results imply sulfasalazine may be related with more severe COVID-19 in AxSpA patients. These patients should be followed more carefully in the presence of COVID-19, regardless of reasons such as age, comorbidity, and extra-axial disease, and consideration of discontinuing sulfasalazine may be even thought.

Keyphrases

coronavirus disease
end stage renal disease
sars cov
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
type diabetes
rheumatoid arthritis
metabolic syndrome
adipose tissue
systemic lupus erythematosus
deep learning